On September 16, 2025, SERB Pharmaceuticals, a global specialty pharmaceutical company focused on rare diseases and medical emergencies, announced the successful completion of its acquisition of Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer. Wilson Sonsini Goodrich & Rosati advised Centerview Partners LLC, the exclusive financial advisor to Y-mAbs Therapeutics, in connection with the transaction.

An all-cash tender offer was initiated on August 18, 2025, and the acquisition was completed on September 16, 2025, following satisfaction of the conditions of the tender offer. The transaction represented an equity value for Y-mAbs of approximately $412 million.

The Wilson Sonsini M&A team that advised Centerview Partners included Rob Ishii, Remi Korenblit, and Nikkisha Smith Howard.

For more information, please see SERB’s news release on the completion of the transaction. The companies’ joint news release announcing the acquisition is available here.